CoronaryAtlas logo
CoronaryAtlas
Lipoprotein(a)
Pathway / Lipid retention & oxidation

Lipoprotein(a)

LPAlipoprotein

Lipoprotein(a) is an ApoB-containing lipoprotein retained in the subendothelial intima where it undergoes oxidative modification; its apo(a) moiety confers independent prothrombotic and pro-inflammatory effects that accelerate atherothrombotic MI.

Pathway placement
Cascade stepLipid retention & oxidation
Confidencehigh
RationaleApoB-lipoprotein variant with independent atherosclerotic and thrombotic risk; retained in intima and oxidized.
Also acts inCoagulation / thrombus
Druggability
DruggableYes
Known drugs / candidates2
Small-molecule tractableYes
Antibody tractableYes
EnsemblENSG00000198670

Type I vs Type II discrimination

ScoresType-II-associated
R — rupture / Type-I
—
C — confounder / Type-II
67
A — assay feasibility
84
E — evidence strength
36
T1DI (composite)
7
Specificity differential (R−C)-52
Confounder panel (Type-II drivers)
1sepsis / systemic inflammationmag 2
2anemia / acute blood lossn/a
3hypovolemia / dehydrationn/a
4tachyarrhythmiamag 2
5hypoxemia / respiratory failuren/a
6hypertensive emergencyn/a
7high-demand / peri-operative stressn/a
Coverage: 2/7 confounders with evidence
Tier: deep-scored (abstract-extracted) · 6 supporting references. See the discrimination table for all markers.

Assay & specimen

Validated clinical assay
Specimen
Serum or plasma
Collection tube
Serum separator (gold/red-top, SST)
Method / principle
Immunoturbidimetric / immunonephelometric (isoform-insensitive preferred)
Reagent / substrate
Anti-apo(a) antibody-latex; report in nmol/L
Platform
Automated analyzer
Turnaround · availability
Routine–send-out · Widely available

Human genetic evidence

0.552
Open Targets association (myocardial_infarction)
18
GWAS associations
Traits: myocardial infarction

Literature evidence(46)

Showing 40 of 46 linked references.

Clinical trials(19)